Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems

The Medtronic advanced hybrid closed-loop (AHCL) and MiniMed (TM) 670G hybrid closed-loop (HCL) systems provide the option to temporarily increase the glucose target to 150 mg/dL (8.3 mmol/L). This analysis investigated the efficacy of the AHCL compared with that of the HCL after the use of this setting. Data from 60 participants in the Fuzzy Logic Automated Insulin Regulation (FLAIR) study were used to compare the AHCL and HCL systems after the use of the temporary target (TT), and during analogous periods where this setting was not used. Differences in time in range 70-180 mg/dL between the systems were similar after the use of the TT setting and during analogous non-TT periods (interaction P = 0.87). Similar trends were observed for mean glucose, percentage time >180 mg/dL, and percentage time >250 mg/dL. Differences between AHCL and HCL systems were similar after the use of the TT setting compared with those of non-TT periods.ClinicalTrials.gov NCT03040414

Automated summary

This analysis compared the efficacy of the Medtronic advanced hybrid closed-loop (AHCL) system with that of the MiniMed (TM) 670G hybrid closed-loop (HCL) system after the temporary increase of glucose target. The study found that there were similar differences in blood glucose control between the two systems after the use of the temporary target setting and during periods where this setting was not used.